The aim of the PREVOS study
(PREVention Of early postmenopausal bone loss by Strontium ranelate) and the
STRATOS study (STRontium Administration for Treatment of OSteoporosis) was to
determine the minimum dose at which strontium ranelate (SR) is effective in,
respectively, the prevention of bone loss in early postmenopausal
nonosteoporotic women and the treatment of postmenopausal vertebral
osteoporosis.
The minimum dose at which SR is
effective in preventing bone loss in early postmenopausal nonosteoporotic women
and in the treatment of postmenopausal osteoporosis is 1 g/day and 2 g/day,
respectively.
Strontium ranelate phase 2 dose-ranging
studies: PREVOS and STRATOS studies, J. Y. Reginster and P. J.
Meunier, Osteoporosis
International, Volume
14, Supplement 3, 56-65, DOI:
10.1007/s00198-002-1349-0
The chemical structure of strontium ranelate is
composed of two atoms of stable strontium combined with organic ranelic acid.
Strontium is the bone active component and makes up 34% by weight of the whole
molecule, so each 2 g dose of strontium ranelate delivers 680 mg of elemental
strontium.